Richard B. Schwab
机构: Senior Medical Director, Genentech
每年引用次数
引用次数
引用: 7,443
H-指数: 42
I10-指数 : 78
出版物: 173
Abstract A212: Next generation sequencing (NGS) in 57 patients with advanced or metastatic breast cancer: Identification of unique genomic profiles and correlation with response.
Jennifer J. Wheler , Barbara A. Parker , Jack Lee , Roman Yelensky
Molecular Cancer Therapeutics 12
2013
Analysis of the association of proteins with membranes.
T. Okamoto , R.B. Schwab , P.E. Scherer , M.P. Lisanti
Current protocols in pharmacology 5 ( 1)
20
2000
Abstract P2-06-01: Breast-to-breast metastasis can cause hormone-receptor positive/triple negative bilateral synchronous tumors
RB Schwab , L Bao , M Pu , B Crain
Cancer Research 72
1
2012
Abstract P4-04-15: UC San Diego molecular tumor board: Experience in breast cancer
BA Parker , RB Schwab , TL Helsten , BG Sarah
Cancer Research 73
2013
Abstract P4-01-05: Cell free DNA analysis identifies actionable ERBB2 amplifications in patients with HER2 equivocal breast cancer
TA Rich , VM Raymond , ER Ahn , KC Banks
Cancer Research 79 ( 4_Supplement) P4 -P4
2019
Genome-wide Sequencing Reveals Signature Mutational Events and Therapeutic Opportunities in Mucinous Carcinoma of the Appendix (MAC)
H Alakus , ML Babicky , S Yost , K Jespen
ANNALS OF SURGICAL ONCOLOGY 21 S12 -S12
2014
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020; 11 (1): 4965
S Kato , KH Kim , HJ Lim , A Boichard
Public Health Genomics 10 32 -32
8
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage, Globo H-Positive, Triple-Negative Breast Cancer
Hope S Rugo , Javier Cortes , Louis WC Chow , Peter A Fasching
Next generation sequencing (NGS) in 57 patients with advanced or metastatic breast cancer: Identification of unique genomic profiles and correlation with response.
Jennifer J Wheler , Barbara A Parker , Jack Lee , Roman Yelensky
MOLECULAR CANCER THERAPEUTICS 12 ( 11)
1
2013
Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome.
Ignacio Garrido-Laguna , Filip Janku , Razelle Kurzrock , Michelle L. Turski
Discovery Medicine 19 ( 103) 109 -116
11
2015
Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome.
Ignacio Garrido-Laguna , Filip Janku , Razelle Kurzrock , Michelle L. Turski
Discovery Medicine 18 ( 101) 323 -330
4
2014
Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies.
Ignacio Garrido-Laguna , Filip Janku , Razelle Kurzrock , Michelle L. Turski
Discovery Medicine 19 ( 103) 101 -108
2015
Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.
Ignacio Garrido-Laguna , Filip Janku , Razelle Kurzrock , Michelle L. Turski
Discovery Medicine 18 ( 101) 331 -339
6
2014
Abstract PD9-04: Identification of biomarkers associated with therapeutic resistance: Quantitative protein/phosphoprotein analysis of ~750 patients across 8 arms of the neoadjuvant I-SPY 2 TRIAL for high-risk early stage breast cancer
Richard Schwab , Rita Nanda , John Park , Christina Yau
Cancer Research 81
2021
Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Heather Beckwith , Richard Schwab , Christina Yau , Erica Stringer-Reasor
Cancer Research 81
1
2021
Abstract PS4-08: Biomarker analysis of paclitaxel, ganitumab, and metformin (PGM) therapy in the I-SPY2 neoadjuvant clinical trial
Douglas Yee , Paul Haluska , Denise M Wolf , Christina Yau
Cancer Research
2021
Abstract OT-13-10: Global Phase 3 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy
Michelle Melisko , Peter A. Fasching , Yen-Shen Lu , Richard Schwab
Cancer Research 81
2021
Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm
Michelle L. Turski , Smruti J. Vidwans , Filip Janku , Ignacio Garrido-Laguna
Molecular Cancer Therapeutics 15 ( 4) 533 -547
64
2016
Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.
Suping Zhang , Han Zhang , Emanuela M. Ghia , Jiajia Huang
Proceedings of the National Academy of Sciences of the United States of America 116 ( 4) 1370 -1377
89
2019
Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Minetta C. Liu , Patricia A Robinson , Christina Yau , Anne M Wallace
Cancer Research
2020